



July 31, 2017

Web Announcement 1418

## **Drug Use Review (DUR) Board Approves Changes Effective August 1, 2017**

The Nevada Medicaid Drug Use Review (DUR) Board met on January 28, 2017, and voted to adopt the following changes effective August 1, 2017:

<b>Drug Class/Program</b>	<b>Changes</b>
Lock-in Program	Allows providers to change the assigned lock-in pharmacy on behalf of the member.
Buprenorphine/Naloxone	Seven-day supply allowed without prior authorization (PA) when pharmacy submits an appropriate diagnosis related to opioid dependence and submits the specified PA code.
Hepatitis C Antivirals, Direct Acting	Added criteria for Epclusa® (Sofosbuvir/Velpatasvir)
Incretin Mimetics	Removed the prior authorization requirement, if a diagnosis related to diabetes is submitted on the claim.
Medication for Recipients on Hospice	All medications require prior authorization for recipients enrolled in the Hospice program regardless of age.
Orkambi® (Lumacaftor/Ivacaftor)	Updated the age to six (6) years old.